…in the event of b), would MNTA go to a royalty position even though there is in fact no third product actually on the market due to pending legal action?
No—MNTA’s profit-share arrangement does not change to a royalty unless a competing generic Lovenox has actual commercial sales.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”